BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34657150)

  • 1. GNA14's interaction with RACK1 inhibits hepatocellular carcinoma progression through reducing MAPK/JNK and PI3K/AKT signaling pathway.
    Xu C; Li YM; Sun B; Zhong FJ; Yang LY
    Carcinogenesis; 2021 Nov; 42(11):1357-1369. PubMed ID: 34657150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor for activated C kinase 1 promotes hepatocellular carcinoma growth by enhancing mitogen-activated protein kinase kinase 7 activity.
    Guo Y; Wang W; Wang J; Feng J; Wang Q; Jin J; Lv M; Li X; Li Y; Ma Y; Shen B; Zhang J
    Hepatology; 2013 Jan; 57(1):140-51. PubMed ID: 22903704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis.
    Duan F; Wu H; Jia D; Wu W; Ren S; Wang L; Song S; Guo X; Liu F; Ruan Y; Gu J
    J Hepatol; 2018 Jun; 68(6):1191-1202. PubMed ID: 29454068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypermethylation of GNA14 and its tumor-suppressive role in hepatitis B virus-related hepatocellular carcinoma.
    Song G; Zhu X; Xuan Z; Zhao L; Dong H; Chen J; Li Z; Song W; Jin C; Zhou M; Xie H; Zheng S; Song P
    Theranostics; 2021; 11(5):2318-2333. PubMed ID: 33500727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
    Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
    Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
    [No Abstract]   [Full Text] [Related]  

  • 6. Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
    Liu C; Peng X; Li Y; Liu S; Hou R; Zhang Y; Zuo S; Liu Z; Luo R; Li L; Fang W
    Biomed Pharmacother; 2020 Mar; 123():109780. PubMed ID: 31901550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma.
    Ruan Y; Sun L; Hao Y; Wang L; Xu J; Zhang W; Xie J; Guo L; Zhou L; Yun X; Zhu H; Shen A; Gu J
    J Clin Invest; 2012 Jul; 122(7):2554-66. PubMed ID: 22653060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
    Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
    Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
    Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
    BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of miR-623 suppresses progression of hepatocellular carcinoma via regulating the PI3K/Akt signaling pathway by targeting XRCC5.
    Ren F; Su H; Jiang H; Chen Y
    J Cell Biochem; 2020 Jan; 121(1):213-223. PubMed ID: 31190447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3K/Akt pathway.
    Wang F; Yamauchi M; Muramatsu M; Osawa T; Tsuchida R; Shibuya M
    J Biol Chem; 2011 Mar; 286(11):9097-106. PubMed ID: 21212275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.
    Ma YS; Wu TM; Qian B; Liu YS; Ding H; Fan MM; Liu JB; Yu F; Wang HM; Shi Y; Gu LP; Li L; Tian LL; Wang PY; Wang GR; Wu ZJ; Zou QF; Ling CC; Fu D
    J Cell Mol Med; 2021 Apr; 25(8):4040-4052. PubMed ID: 33621431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PER1 suppresses glycolysis and cell proliferation in oral squamous cell carcinoma via the PER1/RACK1/PI3K signaling complex.
    Gong X; Tang H; Yang K
    Cell Death Dis; 2021 Mar; 12(3):276. PubMed ID: 33723221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The important role of the receptor for activated C kinase 1 (RACK1) in nasopharyngeal carcinoma progression.
    Peng H; Gong PG; Li JB; Cai LM; Yang L; Liu YY; Yao KT; Li X
    J Transl Med; 2016 May; 14(1):131. PubMed ID: 27170279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway.
    Ni Q; Chen Z; Zheng Q; Xie D; Li JJ; Cheng S; Ma X
    Cancer Sci; 2020 May; 111(5):1500-1513. PubMed ID: 31997489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GNA14 stimulation of KLF7 promotes malignant growth of endometrial cancer through upregulation of HAS2.
    Wang J; Teng F; Chai H; Zhang C; Liang X; Yang Y
    BMC Cancer; 2021 Apr; 21(1):456. PubMed ID: 33892667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathways.
    Lin Z; Li S; Guo P; Wang L; Zheng L; Yan Z; Chen X; Cheng Z; Yan H; Zheng C; Zhao C
    Life Sci; 2019 Feb; 218():197-204. PubMed ID: 30582951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of lncRNA FER1L4 suppresses the proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathway.
    Wang X; Dong K; Jin Q; Ma Y; Yin S; Wang S
    J Cell Biochem; 2019 Apr; 120(4):6781-6788. PubMed ID: 30382631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
    Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
    Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.